pharma · Renal Transplantation · Rheumatoid Arthritis (RA)
Astellas Pharma
Astellas Pharma Inc
Astellas Pharma clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 20
- Drugs
- 12
- Patents
- 25
Astellas Pharma projects
5 ClinicalTrials.gov programs sponsored by Astellas Pharma.
Astellas Pharma has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ASP5094
Astellas Pharma Inc
Rheumatoid Arthritis (RA)
1 trial -
ASP8273
Astellas Pharma Inc
Non-small Cell Lung Cancer
1 trial -
Gilteritinib
Astellas Pharma Inc
Non-Small-Cell Lung Cancer
1 trial -
Tacrolimus
Astellas Pharma Inc
Bone Marrow Transplantation
1 trial -
YM150
Astellas Pharma Inc
Thromboembolism
1 trial
Frequently asked questions
How many clinical projects does Astellas Pharma have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.